Incorporation of deuterium atoms to API’s (active pharmaceutical ingredients) can result in improved stability and pharmacokinetic profile over the parent structures, while retaining their efficacy. Increased strength in carbon-deuterium bonds may allow deuterated compounds to be metabolized at slower rates and used in lower dosages than all hydrogen analogs. We currently focus on the introduction of N-CD3 and/or O-CD3 groups to various drugs such as fluoxetine. In vitro studies of deuterated drugs using CYP3A4 and/or CYP2D6 have been conducted to demonstrate improved metabolic properties over marketed pharmaceutical drugs.

Synthetic and metabolic studies of deuterium labeled drugs

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.